Senti Biosciences (NASDAQ:SNTI) Issues Earnings Results

Senti Biosciences (NASDAQ:SNTI) posted its earnings results on Thursday. The company reported ($0.67) EPS for the quarter, Zacks reports.

Senti Biosciences Stock Performance

SNTI traded down $0.11 during midday trading on Thursday, hitting $3.51. The stock had a trading volume of 16,801 shares, compared to its average volume of 781,284. Senti Biosciences has a 1 year low of $1.52 and a 1 year high of $16.94. The business has a fifty day moving average of $3.95 and a 200 day moving average of $3.44. The company has a market cap of $16.95 million, a P/E ratio of -0.23 and a beta of 2.52.

Analysts Set New Price Targets

Separately, Chardan Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Senti Biosciences in a research note on Monday, December 2nd.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.